Abstract
Aims: Estrogen-dependent hyperplasia of myo- and endometrium manifests as uterine leiomyoma or adenomyosis. We studied possible associations between common polymorphisms of matrix metalloproteinase (MMP) genes and clinical features of uterine hyperplasia. Patients and Methods: One hundred seventy female patients with uterine leiomyoma (46.6±0.5 years) were observed. Clinical diagnosis was based on physical examination, ultrasonography, and histological data. MMP-1 (−1607 1G/2G, rs1799750) and MMP-3 (−1171 5A/6A, rs3025058) were genotyped with allele-specific polymerase chain reaction (PCR) of leukocyte DNA. Clinical and genetic data were evaluated using nonparametric statistics. Results: Distributions of MMP-1 and MMP-3 promoter alleles among patients and population controls were similar and corresponded to the Hardy–Weinberg equilibrium (HWE). Detectable tumor growth and adenomyosis were observed, respectively, in 71% and 55% of cases. Steady-state leiomyoma correlated with a higher prevalence of the MMP-1 1G/1G genotype (p=0.02 by χ2 test). Accelerated tumor growth correlated with higher frequency of the MMP-1 2G allele [odds ratio (OR)=2.048, p=0.039, χ2=4.2611, confidence interval (CI)=(1.032–4.062)]. MMP-1 2G was also associated with multinodular growth [OR=3.561, p=0.01249, χ2=6.24, CI=(1.261–10.058)]. The MMP-1 2G allele tended to increase in patients with adenomyosis [OR=1.525, p=0.054, χ2=3.71, CI=(0.992–2.345)]. Conclusion: Our pilot study suggests that the 2G −1607MMP-1 genotype may be a potential risk marker of myo- and endometrial hyperplasia.
Introduction
Hormone-dependent hyperplasic conditions of endo- and myometrium are quite common in women over their reproductive age. For example, symptomatic uterine leiomyoma (uterine fibroid) is observed in 20%–40% of all women over 35 years of age. Leiomyoma tissue consists of smooth muscle cells and connective tissue components. Adenomyosis (ectopic intrauterine growth of endometrium) and endometrial hyperplasia are also rather common and manifest with abnormal uterine bleeding. Their typical morphology is also well described (McCluggage, 2006). In cases of medication failure, a hysterectomy may be the only treatment option for such conditions (Arena and Zupi, 2011).
Leiomyoma growth is associated with normal cyclic bleedings accompanied by a physiological shedding of functional endometrium, followed by fast epithelial and vascular repair (Ouyang et al., 2006; Blake, 2007; Van Voorhis, 2009). These events are dependent on cyclic fluctuations of estrogen levels, causing periodic induction of cellular growth factors, thus triggering a process similar to wound healing. Hence, leiomyoma is thought to result from abundant proliferation of normal myometrial and endometrial tissues caused by extensive remodeling of extracellular matrix (Salamonsen, 2003; Bodner-Adler et al., 2004; Zhang et al., 2010).
A number of recent genetic studies of leiomyoma and adenomyosis were focused on functional gene variants controlling metabolism of steroid hormones and expression of their receptors (Blake, 2007; Othman and Al-Hendy, 2008; Govindan et al., 2009). Moreover, some evidence was obtained for upregulation of collagen metabolism by sex steroid hormones in uterine leiomyoma (Ohara, 2009).
However, little is known about genetic factors that may directly influence collagen remodeling in myo- and endometrium. An important role of matrix metalloproteinases (MMPs) in malignant tumor growth was shown by many workers (Pepper, 2001; Brauer, 2006). Similar effects of MMPs upon leiomyoma growth may be also suggested. For example, interstitial collagenase (matrix metalloproteinase-1 or MMP-1) is of special importance, since it performs an initial cleavage of native type I and III collagen molecules, whereas stromelysin (MMP-3) performs the next step of collagen degradation. In fact, increased local expression of pro-MMP-1 and pro-MMP-3 mRNAs was revealed in uterine tissue during menstrual bleeding (Curry and Osteen, 2003).
For the MMP-1 promoter, a well-known polymorphic site is described, that is, a 1G/2G insertion/deletion at the −1607 position. The 2G (insertion) allele exhibits an additional binding site for Ets, an estrogen-sensitive transcription factor, thus providing higher synthesis of pro-MMP-1 mRNA (Ye et al., 2001). A homozygous 2G/2G state is found to be associated with a higher risk of invasion and/or metastases in several types of malignant tumors (Fingleton, 2006; Zhou et al., 2011). Similarly, an MMP-3 gene polymorphism displays functional variants at the −1171 position (5A/6A genotype). The 5A allele is characterized by increased transcription levels mediated by ZBP-89, or NFκB transcription factors (Borghaei et al., 2009; Souslova et al., 2010), being associated with a higher incidence of breast cancer and lung tumors (Ghilardi et al., 2002; Brauer, 2006).
In the available literature, we have not found any data concerning associations between these functional gene variants and cell proliferation rates in benign conditions, including uterine leiomyoma and adenomyosis. Only a single study addressed incidence of uterine leiomyoma and an MMP-1 1G/2G polymorphism in Japanese women (Takemura et al., 2006). Data on genetic predisposition for endometriosis are often inconsistent, except for estrogen receptor gene polymorphisms (Shan et al., 2005; Montgomery et al., 2008).
The aim of the present study was to compare allele frequencies for 2 common MMP-1 and MMP-3 gene polymorphisms in clinical subgroups of patients with different types of leiomyoma growth and adenomyosis. Some significant associations were revealed between a highly expressed 2G promoter allele of MMP-1 and tissue growth characteristics for different clinical subgroups.
Patients and Methods
Clinical characteristics
A group of one hundred seventy women was observed at the Department of Surgical Gynecology (St. Petersburg Medical Academy of Postgraduate Education) for up to 5 years, due to uterine leiomyoma (both symptomatic and latent cases) or endometrial pathology (for clinical details, see Table 1). Any patients with proven malignant tumors or atypical endometrial or cervical hyperplasia have been excluded from further analysis, in particular, patients with hormone-secreting ovarian tumors and malignant breast neoplasms. The women were 26–63-year old (mean age was 46.2±0.5 years). A control age-matched group (122 persons) consisted of female healthy donors of blood or bone marrow admitted to St. Petersburg State Medical University. The study was initiated and performed under written consent and understanding of each participating patient, in compliance with the Code of Ethics of the World Medical Association, according to the Declaration of Helsinki. The entire study design and all diagnostic procedures were approved and observed by the local Ethics Board at the St. Petersburg Medical Academy of Postgraduate Education.
Table 1.
| Clinical feature | Number of cases | Percent of total (%) | Premenopausal patients, mean duration, years (M+m) | Menopausal patients, mean duration, years (M+m) | p Value |
|---|---|---|---|---|---|
| Disease duration | |||||
| 10 years | 27 | 15.9 | 9.2±0.6 | 18.3±1.5a | 0.2 |
| 3–4 | 42 | 24.7 | 22.7% (35) | 43.8% (7)a | 0.03 |
| ≥5 | 42 | 24.7 | 27.3% (42) | 0a | 0.03 |
| Growth rates | |||||
| Steady-state | 41 | 29.3 | 18.4% (23/125) | 46.7% (7/15) | >0.2 |
| Slow growth | 69 | 49.3 | 50.4% (63/125) | 40.0% (6/15) | >0.2 |
| Rapid growth | 30 | 21.4 | 31.2% (39/125) | 13.0% (2/15)a | 0.03 |
| State of endometrium | |||||
| Normal range | 72 | 42.3 | 46.8% (72/154) | 0.0 (0/16) | >0.2 |
| Glandular hyperplasia | 33 | 19.5 | 20.8% (32/154) | 6.3% (1/16) | >0.2 |
| Atrophia | 18 | 10.6 | 5.8% (9/154) | 56.3% (9/16)a | 0.2 |
| Adenomyosis | 93 | 54.7 | 59.7% (92/154) | 6.3% (1/16)a | 0.2 |
| Menorrhagia | 120 | 70.4 | 74.0% (114/154) | 37.5% (6/16) | 0.02 |
| Breast pathology | 144 | 84.7 | 28.6% (26/91) | 6.3% (1/16)a | <0.001 |
| Obesity | 49 | 28.7 | 33.1% (51/154) | 37.5% (6/16)a | 0.02 |
The difference between premenopausal and menopausal patients is significant by p<0.05.
Symptomatic uterine disorders were characterized by menorrhagia, rapid leiomyoma progression (for evaluation methods, see below), and multinodular growth. The diagnosis was confirmed clinically and histologically of available surgical samples. Clinical studies included transabdominal ultrasonography of pelvic organs by means of the General Electric Logiq 500 model (or Acuson Aspen; Siemens). General examination of the ovaries was also performed. Uterine volume, location, and number of fibroid nodules were determined on basis of ultrasonographic data (Shaw, 1998).
Long-term tumor progression evaluated in a time-dependent manner, according to echographic examinations performed semiannually (up to 5 years of observation), was available for a subgroup of 140 patients. Longitudinal (A), transverse (B), and sagittal dimensions of the tumor-bearing uterus were registered, and the total organ volume was calculated as follows: V(cm3)=π/6×A×B×C. Rapid tumor growth was registered if it exceeded 50 cm3 per year. Absence of growth was confirmed if the measurable size of uterus was decreased or remained constant upon observation.
Hysteroscopic examinations were performed with a surgical device (Axioma) by means of a standard approach, using liquid media. Uterine and cervical curettage was performed in cases of proven adenomyosis, submucous leiomyoma, or polyposis. Endometrial specimens were taken upon hysteroscopy or by means of aspiration biopsies. Histological evaluation of endometrial samples has been performed according to the Third Revision of the International WHO Classification of female genital tumors (Abeler et al., 2003).
One hundred twenty-two patients with symptomatic leiomyoma or endometrial disorders were surgically treated. Forty-eight patients (28.2% of total group) were subjected to conservative treatment by the antiestrogenic phytohormones. Other steroid drugs or GnRH analogs were omitted from our treatment schedules.
Genotyping procedures
To study the genetic aspects of leiomyoma growth, we performed genotyping of common promoter alleles for MMP-1 (−1607 1G/2G) and MMP-3 (−1171 5A/6A). In brief, genomic DNA was isolated from blood leukocytes of patients and donors using a batch sorbent technique (DNA Sorb commercial kit; Lytech). All the studied gene polymorphisms were detected by means of allele-specific polymerase chain reaction (PCR). Specific DNA probes were designed using Primer Express software (Applied Biosystems), placing the target point mutation at the 3′ end of the forward primers. Details of primers and amplicons are shown in Table 2.
Table 2.
| Alleles tested | Forward primer (5′–3′) | Reverse primer (5′–3′) | Amplicon length (bp) |
|---|---|---|---|
| MMP-1−1607 | |||
| 1G | gaa att gta gtt aaa taa tta gaa aga t | aaa aca tac agt gga gaa aca c | 226 |
| 2G | aaa ttg tag tta aat aat tag aaa gga | tgg aag cat tta ttg aaa ac | 241 |
| MMP-3−1171 | |||
| 5A | ttg atg ggg gga aaa ac | act cca gag aaa att tac aaa gg | 226 |
| 6A | ttg atg ggg gga aaa aa | aac ata tta tct atc agg ctt tcc t | 282 |
MMP, matrix metalloproteinase.
PCR mixtures contained the following standard components: 5× PCR buffer stock solution with xylene cyanol and glycerol (InterLabService); standard dNTPs (MBI Fermentas); specific primers (Syntol) at the final concentrations of 0.05–0.3 μM; and 1 IU of Taq polymerase (DNA-Technology). About 17.5 μL of the PCR mixture was added to 2.5 μL of DNA. DNA was amplified in the ICycler (Bio-Rad). The standard PCR schedule was as follows: initial denaturation at 94°C, 5 min; 40 PCR cycles consisting of denaturation step, 94°C, 30 s; annealing for 30 s at 55°C (MMP-1), 54°C (MMP-3 5A), and 49°C, (MMP-3 6A); and elongation (72°C, 30 s), followed by final extension of amplified segments (72°C, 7 min.). PCR products were evaluated after electrophoresis in a 1.5% agarose gel under ethidium bromide staining and visualized in an ultraviolet transilluminator. The pictures were captured by means of the digital camera Canon PowerShot A70. Accuracy of testing was checked by repeated genotyping and sequencing of PCR products for allelic polymorphisms under study.
Data evaluation
Genotype distributions were statistically evaluated by means of STATISTICA 6.0 software. Significance of the differences obtained was assessed by nonparametric criteria (χ2 test, Spearman criterion). The allele frequencies were calculated for separate clinical subgroups and population controls. The 95% confidence intervals (CIs) of allele frequencies were calculated based on a binomial distribution. Tests for deviations from the Hardy–Weinberg equilibrium (HWE) were performed for all subgroups, by Pearson's goodness-of-fit χ2 criterion, using the DeFinetti approach (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl). A p-value of 0.05 was considered statistically significant.
Results
As seen from Table 1, mean clinical history of leiomyoma did not exceed 5 years in most women (58.9%). Numbers of detectable tumor nodes were quite variable (1 to >5). Rapid growth of tumor was noted in 21% of patients, whereas a steady-state or regressing leiomyoma was revealed in 29%. Adenomyosis was the most common gynecological disorder that accompanied uterine leiomyoma (54.7% of total group).
A primary analysis of genetic data has shown that all MMP genotypes and alleles under study were rather uniformly represented in the clinical samples and population controls (Table 3), and their frequencies did not significantly differ from those in the European population (Zhang et al., 2001; Ghilardi et al., 2002, a total of 391 persons), by appropriate p-values of 0.838 and 0.899 for MMP-1 1G/2G and MMP-3 5A/6A, respectively. Tests for deviation from the HWE did not show any differences from expected distributions in our control group. The respective χ2 values were 1.19 for MMP-1 1G/2G and 0.16 for MMP-3 5A/6A. We could not find any significant differences in MMP-1 and MMP-3 genotypes or allelic frequencies between the leiomyoma and control groups (see Table 3).
Table 3.
| Genes studied | Number of cases | MMP promoter genotypes | MMP promoter alleles | OR (95% CI) | ||||
|---|---|---|---|---|---|---|---|---|
| MMP-1 1G/2G−1607 | 1G/1G | 1G/2G | 2G/2G | 1G | 2G | |||
| Leiomyoma patients | 170 | n | 45 | 87 | 38 | 177 | 163 | 0.96 (0.696–1.344), χ2=0.04, p=0.843 |
| f | 0.27 | 0.51 | 0.22 | 0.52 | 0.48 | |||
| Controls | 122 | n | 29 | 67 | 26 | 125 | 119 | |
| f | 0.24 | 0.55 | 0.21 | 0.51 | 0.49 | |||
| MMP-3 5A/6A−1171 | 5A/5A | 5A/6A | 6A/6A | 5A | 6A | |||
| Leiomyoma patients | 170 | n | 35 | 92 | 43 | 162 | 178 | 1.099 (0.775–1.558), χ2=0.28, p=0.597 |
| f | 0.21 | 0.54 | 0.25 | 0.48 | 0.52 | |||
| Controls | 100 | n | 26 | 48 | 26 | 100 | 100 | |
| f | 0.26 | 0.48 | 0.26 | 0.50 | 0.50 |
Genetic data are expressed as absolute numbers (n) of distinct genotypes or alleles, and their frequencies (f) for the groups studied.
OR, odds ratio; CI, confidence interval.
Upon classification of leiomyoma cases by their severity, the patients with rapid growth rates proved to exhibit a lower frequency of the MMP-1 1G/1G genotype (Table 4) as compared with higher incidence of this genotype among women with steady-state/regressing tumors [odds ratio (OR)=4.250, p=0.007, χ2=7.28, CI=(1.437–12.572)], thus suggesting a sufficient protective role of the MMP-1 1G/1G genotype, with regard to inhibition of myometrial cell proliferation. Meanwhile, an increased frequency of the 2G allele proved to be associated with excessive tumor growth [OR=2.048, p=0.039, χ2=4.2611, CI=(1.032–4.062)].
Table 4.
| |
|
|
MMP1−1607 promoter genotypes |
|
Allele numbers and frequencies |
|
|||
|---|---|---|---|---|---|---|---|---|---|
| Clinical features | Number of cases | 1G/1G | 1G/2G | 2G/2G | p | 1G | 2G | p | |
| Growth rates | |||||||||
| Regression/no growth | 30 | n | 14 | 11 | 5 | 39 | 21 | ||
| f | 0.47 | 0.37 | 0.16 | 0.65 | 0.35 | ||||
| Slow growth | 69 | n | 19 | 32 | 18 | 70 | 68 | ||
| f | 0.28 | 0.46 | 0.26 | 0.51 | 0.49 | ||||
| Rapid growth | 41 | n | 7 | 25 | 9 | 0.007a | 39 | 43 | 0.039a |
| f | 0.17 | 0.61 | 0.22 | 0.48 | 0.52 | ||||
| Number of nodes | |||||||||
| 1–2 nodes | 86 | n | 29 | 41 | 16 | 99 | 73 | ||
| f | 0.34 | 0.48 | 0.18 | 0.58 | 0.42 | ||||
| 3–4 nodes | 44 | n | 11 | 23 | 10 | 45 | 43 | ||
| f | 0.25 | 0.52 | 0.23 | 0.51 | 0.49 | ||||
| ≥5 nodes | 40 | n | 5 | 23 | 12 | 0.015b | 33 | 47 | 0.013b |
| f | 0.13 | 0.58 | 0.29 | 0.41 | 0.59 | ||||
| Adenomyosis | |||||||||
| Non-detectable | 77 | n | 28 | 33 | 16 | 89 | 65 | ||
| f | 0.36 | 0.43 | 0.21 | 0.58 | 0.42 | ||||
| Detectable | 93 | n | 17 | 54 | 22 | 0.008c | 88 | 98 | 0.054c |
| f | 0.18 | 0.58 | 0.24 | 0.47 | 0.53 |
Clinical data on long-term tumor growth rates were available for 140 cases out of 170. Numbers of genotypes or alleles (n) and their frequencies (f) are shown for the clinical subgroups studied.
p Values show levels of significance for different subgroups.
The difference in genotype distribution or allele frequencies between steady-state and growing tumor groups.
The difference in genotype distribution or allele frequencies between mono- and multinodular tumor groups.
The difference in genotype distribution or allele frequencies between patients with adenomyosis and adenomyosis-free cases.
As seen from Table 4, a lower frequency of the 1G/1G genotype of MMP-1 was revealed among women with multinodular forms of leiomyoma (Table 4), p=0.015. Accordingly, harboring the 2G allele seems to be a risk factor for multinodular leiomyoma growth [OR=3.561, p=0.013, χ2=6.24, CI=(1.261–10.058)].
The frequency of the 1G/1G genotype was also markedly decreased in patients with adenomyosis (p=0.008, by χ2 test), thus, probably, reflecting its protective effects against ectopic endometrial proliferation [OR=2.555, p=0.008, χ2=7.08, CI=(1.267–5.152)]. We have also noted a trend for association between the MMP-1 2G allele and a higher risk of adenomyosis [OR=1.525, p=0.054, χ2=3.71, CI=(0.992–2.345)].
We have also studied relative frequencies of the 5A and 6A alleles of the MMP-3 gene, which is closely linked to MMP-1. Analysis of these data did not reveal any significant correlations with the above-mentioned clinical features of leiomyoma or adenomyosis (data not shown). Hence, some significant correlations were found between proliferative disorders of uterine tissue and the promoter polymorphism of MMP-1, but not with MMP-3 promoter variants.
Discussion
We have performed genotyping of 2 common promoter polymorphisms of MMP-1 and MMP-3 genes. Both genes were mapped in proximity on chromosome 11q21-22, and some MMP-1 polymorphisms were shown to correlate with serum levels of MMP-1 protein (Cheng et al., 2009). All positive findings in our study concerned the MMP-1 polymorphism, thus presuming its specific association with these benign hyperplasic conditions.
A representative group of women with uterine disorders participated in our study. Their mean age (46.6±0.5 years) corresponds to a peak of uterine leiomyoma incidence in the general population. Overall data analysis has shown a correlation between rapid tumor growth and lower frequency of the MMP-1−1607 1G/1G genotype, compared with steady-state tumors. Thus, one may suspect a specific protective role of this MMP-1 variant in local remodeling of the extracellular matrix. Meanwhile, the high-producer 2G promoter allele seems to be associated with excessive leiomyoma growth and an increased number of tumor nodes. In fact, some studies have shown increased levels of specific mRNA transcription and synthesis of appropriate pro-MMP in cells harboring more active MMP-1 and MMP-3 promoter alleles (Ye et al., 2001; Souslova et al., 2010).
Increased MMP-1 activity in myometrium may be induced in cyclic manner by certain growth factors and proinflammatory cytokines (Inagaki et al., 2003; Salamonsen, 2003). These studies discuss a complex role of sex steroid hormones and hormone-inducible growth factors in MMP-1 production, enhanced collagenolysis, and connective tissue remodeling, thus, probably, leading to more intensive proliferation of smooth muscle cells and fibroblasts and consequently, to increased growing potential of leiomyoma.
Similar interactions may be true for excessive endometrial cell proliferation. In patients with adenomyosis, we have shown a decreased percentage of the MMP-1 1G/1G genotype, as well as an increased frequency of the 2G allele. Hence, female carriers of the 2G allele seem to get into the high-risk subgroup that requires a more thorough clinical monitoring for adenomyosis/endometriosis and their complications. A study in a Chinese population has revealed a more frequent incidence of adenomyosis in homozygotes for the 2G allele, thus suggesting a sufficient role of this gene variant in this disorder (Shan et al., 2005).
Moreover, a role of neoangiogenesis is universally recognized for both myo- and endometriosis (Fleischer et al., 2008). MMPs participate in growth-associated destruction of the extracellular matrix, thus creating an additional space for expansion of capillaries and neovascularization of proliferating tissues, either myo-, or endometrium. Therefore, MMPs may be regarded as potential molecular targets for specific enzyme inhibitors that are now widely tested in clinical studies (Jarvelainen et al., 2009).
The results of our study are quite preliminary, and these genetic associations should be confirmed in other female populations. In conclusion, we may suggest an association between harboring the 2G−1607 MMP-1 allele and clinical features of uterine leiomyoma and adenomyosis. The 2G promoter variant of MMP-1 may be considered as a potential gene marker of a more rapid and extensive growth in hormone-dependent female reproductive tissues. In the future, it may be associated with individual risk prediction of severe clinical complications in uterine leiomyoma and adenomyosis.
Acknowledgments
We appreciate the clinical and laboratory personnel who participated in this study. We thank Prof. Boris Fehse (University Clinic Hamburg-Eppendorf) for support in development and validation of genotyping techniques. This work was supported by a research grant from the Russian Ministry of Education and Science, Contract No. 14.740.11.0167, and by a grant from the St. Petersburg City Administration for young scientists and postdoctoral fellows (E.B.M.).
Author Disclosure Statement
No competing financial interests exist.
References
- Abeler M. Albores-Saavedra J. Alvarado-Cabrero I, et al. Tumors of the uterine corpus. In: Tavassoli F, editor; Deville P, editor. Pathology and Genetics of Tumors of the Breast and Female Genital Organs. IARC Press; Lyon: 2003. pp. 217–258. [Google Scholar]
- Arena S. Zupi E. Heavy menstrual bleeding: considering the most effective treatment option. Women's Health. 2011;7:143–146. doi: 10.2217/whe.11.1. [DOI] [PubMed] [Google Scholar]
- Blake RE. Leiomyomata uteri: hormonal and molecular determinants of growth. J Nat Med Assoc. 2007;99:1170–1184. [PMC free article] [PubMed] [Google Scholar]
- Bodner-Adler B. Bodner K. Kimberger O, et al. Expression of matrix metalloproteinases in patients with uterine smooth muscle tumors: an immunohistochemical analysis of MMP-1 and MMP-2 protein expression in leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma. J Soc Gynecol Invest. 2004;11:182–186. doi: 10.1016/j.jsgi.2003.09.004. [DOI] [PubMed] [Google Scholar]
- Borghaei RC. Gorski G. Javadi M, et al. NF-kappaB and ZBP-89 regulate MMP-3 expression via a polymorphic site in the promoter. Biochem Biophys Res Commun. 2009;382:269–273. doi: 10.1016/j.bbrc.2009.03.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Brauer PR. MMPs––role in cardiovascular development and disease. Front Biosci. 2006;11:447–478. doi: 10.2741/1810. [DOI] [PubMed] [Google Scholar]
- Cheng YC. Kao WHL. Mitchell BD, et al. Genome-wide association scan identifies variants near matrix metalloproteinase (MMP) genes on chromosome 11q21-22 strongly associated with serum MMP-1 levels. Circ Cardiovasc Genet. 2009;2:329–337. doi: 10.1161/CIRCGENETICS.108.834986. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Curry TE., Jr. Osteen KG. The matrix metalloproteinase system: changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. Endocr Rev. 2003;24:428–465. doi: 10.1210/er.2002-0005. [DOI] [PubMed] [Google Scholar]
- Fingleton B. Matrix metalloproteinases: role in cancer and metastasis. Front Biosci. 2006;11:479–491. doi: 10.2741/1811. [DOI] [PubMed] [Google Scholar]
- Fleischer R. Weston GC. Vollenhoven BJ, et al. Pathophysiology of fibroid disease: angiogenesis and regulation of smooth muscle proliferation. Best Pract Res Clin Obstet Gynaecol. 2008;22:603–614. doi: 10.1016/j.bpobgyn.2008.01.005. [DOI] [PubMed] [Google Scholar]
- Ghilardi G. Biondi ML. Caputo M, et al. A single nucleotide polymorphism in the MMP-3 promoter enhances breast cancer susceptibility. Clin Cancer Res. 2002;8:3820–3823. [PubMed] [Google Scholar]
- Govindan S. Shaik NA. Vedicherla B, et al. Estrogen receptor-alpha gene (T/C) Pvu II polymorphism in endometriosis and uterine fibroids. Dis Markers. 2009;26:149–154. doi: 10.3233/DMA-2009-0625. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Inagaki N. Ung L. Otani T, et al. Uterine cavity matrix metalloproteinases and cytokines in patients with leiomyoma, adenomyosis or endometrial polyp. Eur J Obstet Gynecol Reprod Biol. 2003;111:197–203. doi: 10.1016/s0301-2115(03)00244-6. [DOI] [PubMed] [Google Scholar]
- Jarvelainen H. Sainio A. Koulu M, et al. Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev. 2009;61:198–223. doi: 10.1124/pr.109.001289. [DOI] [PMC free article] [PubMed] [Google Scholar]
- McCluggage WG. My approach to the interpretation of endometrial biopsies and curettings. J Clin Pathol. 2006;59:801–812. doi: 10.1136/jcp.2005.029702. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Montgomery GW. Nyholt DR. Zhao ZZ, et al. The search for genes contributing to endometriosis risk. Hum Reprod Update. 2008;14:447–457. doi: 10.1093/humupd/dmn016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pepper MS. Role of the matrix metalloproteinase and plasminogen activator plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol. 2001;21:1104–1117. doi: 10.1161/hq0701.093685. [DOI] [PubMed] [Google Scholar]
- Ohara N. Sex steroidal modulation of collagen metabolism in uterine leiomyomas. Clin Exp Obstet Gynecol. 2009;36:10–11. [PubMed] [Google Scholar]
- Othman EE. Al-Hendy A. Molecular genetics and racial disparities of uterine leiomyomas. Best Pract Res Clin Obstet Gynaecol. 2008;22:589–601. doi: 10.1016/j.bpobgyn.2008.01.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ouyang DW. Economy KE. Norwitz ER. Obstetric complications of fibroids. Obstet Gynecol Clin North Am. 2006;33:153–169. doi: 10.1016/j.ogc.2005.12.010. [DOI] [PubMed] [Google Scholar]
- Salamonsen LA. Tissue injury and repair in the female human reproductive tract. Reproduction. 2003;125:301–311. doi: 10.1530/rep.0.1250301. [DOI] [PubMed] [Google Scholar]
- Shan K. Ying W. Jian-Hui Z, et al. The function of the SNP in the MMP1 and MMP3 promoter in susceptibility to endometriosis in China. Mol Hum Reprod. 2005;11:423–427. doi: 10.1093/molehr/gah177. [DOI] [PubMed] [Google Scholar]
- Shaw RW. Gonadotropin hormone–releasing hormone analogue treatment of fibroids. Bailliers Clin Obstet Gynaecol. 1998;12:245–267. doi: 10.1016/s0950-3552(98)80063-1. [DOI] [PubMed] [Google Scholar]
- Souslova V. Townsend PA. Mann J, et al. Allele-specific regulation of matrix metalloproteinase-3 gene by transcription factor NFκB. PLoS ONE. 2010;5:e9902. doi: 10.1371/journal.pone.0009902. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Takemura N. Yoshida S. Kennedy S, et al. Matrix metalloproteinase-1 and −9 promoter polymorphism are not associated with an increased risk of uterine leiomyomas in a Japanese population. J Soc Gynecol Invest. 2006;13:232–236. doi: 10.1016/j.jsgi.2006.02.004. [DOI] [PubMed] [Google Scholar]
- Van Voorhis B. A 41-year-old woman with menorrhagia, anemia, and fibroids: review of treatment of uterine fibroids. JAMA. 2009;301:82–93. doi: 10.1001/jama.2008.791. [DOI] [PubMed] [Google Scholar]
- Ye S. Dhillon S. Turner SJ, et al. Invasiveness of cutaneous melanoma is influenced by matrix metalloproteinase 1 gene polymorphism. Cancer Res. 2001;61:1296–1298. [PubMed] [Google Scholar]
- Zhang B. Dhillon S. Geary I, et al. Polymorphisms in matrix metalloproteinase-1, -3, -9, and -12 genes in relation to subarachnoid hemorrhage. Stroke. 2001;32:2198–2202. doi: 10.1161/hs0901.095382. [DOI] [PubMed] [Google Scholar]
- Zhang X. Qi C. Lin J. Enhanced expressions of matrix metalloproteinase (MMP)-2 and -9 and vascular endothelial growth factors (VEGF) and increased microvascular density in the endometrial hyperplasia of women with anovulatory dysfunctional uterine bleeding. Fertil Steril. 2010;93:2362–2367. doi: 10.1016/j.fertnstert.2008.12.142. [DOI] [PubMed] [Google Scholar]
- Zhou J. Brinckerhoff C. Lubert S, et al. Analysis of matrix metalloproteinase-1 gene polymorphisms and expression in benign and malignant breast tumors. Cancer Invest. 2011;29:599–607. doi: 10.3109/07357907.2011.621915. [DOI] [PMC free article] [PubMed] [Google Scholar]
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.